Enhanced Genomics extends Series A funding to drive development of therapeutics pipeline
Enhanced’s 3D multi-omics platform delivers genetically validated targets for common diseases
24 Sept 2025
Dietrich A. Stephan, Ph.D., Chair, Enhanced Genomics
Enhanced Genomics has announced it has completed a financing round, extending its total Series A funding to $19 million. Investors in this latest funding are BGF, Parkwalk and Meltwind.
The funding will be used to expand Enhanced Genomics' internal therapeutic pipeline in common diseases, including autoimmune conditions such as inflammatory bowel disease. The latest investment will enable Enhanced Genomics to scale its output through strategic partnerships with pharma and biotech, leveraging novel target identification and asset-based opportunities to drive long-term growth.
Enhanced Genomics is the only biotechnology company capable of sourcing genetically-validated targets for complex genetic diseases, where there is significant unmet medical need. The Enhanced Genomics' proprietary 3D multi-omics platform and cell type-specific atlas make it possible to define causal biology from disease-associated variants on a genome-wide scale in the most relevant cell types.
By translating massive amounts of disease-associated data into actionable insights, Enhanced Genomics is identifying high confidence targets with strong genetic evidence of causality, increasing the probability of success in pharmaceutical development, and in a fraction of the time and cost previously possible.
“Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.” said Dietrich A. Stephan, Ph.D., Chair, Enhanced Genomics.
“This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision,” he added.